Literature DB >> 22659388

Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis.

Vibe Skov1, Mads Thomassen, Caroline H Riley, Morten K Jensen, Ole Weis Bjerrum, Torben A Kruse, Hans Carl Hasselbalch, Thomas Stauffer Larsen.   

Abstract

The recent discovery of the Janus activating kinase 2 V617F mutation in most patients with polycythemia vera (PV) and half of those with essential thrombocythemia (ET) and primary myelofibrosis (PMF) has favored the hypothesis of a biological continuum from ET over PV to PMF. We performed gene expression profiling of whole blood from control subjects (n = 21) and patients with ET (n = 19), PV (n = 41), and PMF (n = 9) using DNA microarrays. Applying an unsupervised method, principal component analysis, to search for patterns in the data, we demonstrated a separation of the four groups with biological relevant overlaps between the different entities. Moreover, the analysis separates Janus activating kinase 2-negative ET patients from Janus activating kinase 2-positive ET patients. Functional annotation analysis demonstrates that clusters of gene ontology terms related to inflammation, immune system, apoptosis, RNA metabolism, and secretory system were the most significantly deregulated terms in the three different disease groups. Our results yield further support for the hypothesis of a biological continuum originating from ET over PV to PMF. Functional analysis suggests an important implication of these gene ontology clusters in the pathogenesis of these neoplasms and in disease evolution from ET over PV to PMF.
Copyright © 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659388     DOI: 10.1016/j.exphem.2012.05.011

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  20 in total

1.  A new internet-based tool for reporting and analysing patient-reported outcomes and the feasibility of repeated data collection from patients with myeloproliferative neoplasms.

Authors:  Nana Brochmann; Ann-Dorthe Zwisler; Mette Kjerholt; Esben Meulengracht Flachs; Hans Carl Hasselbalch; Christen Lykkegaard Andersen
Journal:  Qual Life Res       Date:  2015-09-11       Impact factor: 4.147

2.  Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.

Authors:  Vibe Skov; Mads Thomassen; Lasse Kjær; Christina Ellervik; Morten Kranker Larsen; Trine Alma Knudsen; Torben A Kruse; Hans C Hasselbalch
Journal:  PLoS One       Date:  2022-06-30       Impact factor: 3.752

3.  Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.

Authors:  Raajit Rampal; Fatima Al-Shahrour; Omar Abdel-Wahab; Jay P Patel; Jean-Philippe Brunel; Craig H Mermel; Adam J Bass; Jennifer Pretz; Jihae Ahn; Todd Hricik; Outi Kilpivaara; Martha Wadleigh; Lambert Busque; D Gary Gilliland; Todd R Golub; Benjamin L Ebert; Ross L Levine
Journal:  Blood       Date:  2014-04-16       Impact factor: 22.113

Review 4.  Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.

Authors:  Jacob Grinfeld; Jyoti Nangalia; Anthony R Green
Journal:  Haematologica       Date:  2016-12-01       Impact factor: 9.941

Review 5.  Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies.

Authors:  Vincenzo Nasillo; Giovanni Riva; Ambra Paolini; Fabio Forghieri; Luca Roncati; Beatrice Lusenti; Monica Maccaferri; Andrea Messerotti; Valeria Pioli; Andrea Gilioli; Francesca Bettelli; Davide Giusti; Patrizia Barozzi; Ivana Lagreca; Rossana Maffei; Roberto Marasca; Leonardo Potenza; Patrizia Comoli; Rossella Manfredini; Antonino Maiorana; Enrico Tagliafico; Mario Luppi; Tommaso Trenti
Journal:  Int J Mol Sci       Date:  2021-02-14       Impact factor: 5.923

6.  The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms.

Authors:  Mads Emil Bjørn; Hans Carl Hasselbalch
Journal:  Clin Case Rep       Date:  2015-05-04

7.  Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway.

Authors:  Vladan P Čokić; Pascal Mossuz; Jing Han; Nuria Socoro; Bojana B Beleslin-Čokić; Olivera Mitrović; Tijana Subotički; Miloš Diklić; Danijela Leković; Mirjana Gotić; Raj K Puri; Constance Tom Noguchi; Alan N Schechter
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

8.  Transcriptional profiling of whole blood identifies a unique 5-gene signature for myelofibrosis and imminent myelofibrosis transformation.

Authors:  Hans Carl Hasselbalch; Vibe Skov; Thomas Stauffer Larsen; Mads Thomassen; Caroline Hasselbalch Riley; Morten K Jensen; Ole Weis Bjerrum; Torben A Kruse
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

9.  Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression.

Authors:  Hans Carl Hasselbalch; Mads Thomassen; Caroline Hasselbalch Riley; Lasse Kjær; Thomas Stauffer Larsen; Morten K Jensen; Ole Weis Bjerrum; Torben A Kruse; Vibe Skov
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

Review 10.  Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms.

Authors:  Gregor Hoermann; Georg Greiner; Peter Valent
Journal:  Mediators Inflamm       Date:  2015-10-12       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.